Physiotherapy in Hypoxic AECOPD Patients
2. mars 2020 oppdatert av: Marie Carmen Valenza, Universidad de Granada
Feasibility and Efficacy of Physiotherapy in Hypoxic AECOPD Patients
Hypoxia is considered a key player in many of the comorbidities that characterize COPD, such as pulmonary hypertension, skeletal muscle dysfunction, and systemic inflammation.
These comorbidities are worsened during an exacerbation due to prolonged bed rest and treatment with steroids, showing a reduction in the quality of life, exercise tolerance, and a greater risk of death in these patients.
Therefore, a better understanding of the safety and effectiveness of exercise training for AECOPD patients with resting hypoxemia is needed.
Studieoversikt
Status
Ukjent
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Forventet)
36
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Granada
-
Granada., Granada, Spania, 18071
- Rekruttering
- Faculty of Health Sciences. University of Granada.
-
Ta kontakt med:
- Marie Carmen Valenza, PT
- Telefonnummer: 958 248035
- E-post: cvalenza@ugr.es
-
Hovedetterforsker:
- Marie Carmen Valenza, PT, PhD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
40 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients of both sexes
- A diagnosis of COPD made according to the criteria of the American Thoracic Society (ATS)
- With hypoxemia at rest defined as mean arterial oxygen saturation below 90%
- Agreed to participate
Exclusion Criteria:
- Unstable cardiovascular disease
- Orthopedic diseases in the upper and lower limbs
- Being in ICU or use of mechanical ventilation
- Motor sequelae from a neurological or cognitive impairment that interfere with the evaluation and the treatment
- Contraindications of electrotherapy
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Global Exercise Group
all patients received the Control Group treatment added to global exercise treatment.
The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises.
The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
The number of repetitions was adapted to the subject's response taken into account the perceived dyspnea and fatigue during the exercise performance.
|
The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises.
The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
|
|
Eksperimentell: Functional Electrostimulation Group
all patients received the Control Group treatment plus neuromuscular stimulation therapy (SEFAR Rehab X2, DJO France S.A.S., France) on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017). Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103. |
The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017). Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103. |
|
Aktiv komparator: Standard treatment
Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy.
|
Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Lower limb strength
Tidsramme: Baseline
|
Quadriceps strength was assessed with a portable hand-held dynamometer (Lafayette Manual Muscle Testing System, model 01163, Lafayette, IN, USA).
The test was performed with the patient seated with his/her knees and hips flexed at 90°.
Resistance was applied to the anterior tibia during 5 seconds of maximal muscle contraction.
The test was repeated alternatively 3 times on the leg, allowing participants to rest between measurements.
The highest value in Newton was selected for the analysis.
|
Baseline
|
|
Lower limb strength
Tidsramme: Up to 9 days
|
Quadriceps strength was assessed with a portable hand-held dynamometer (Lafayette Manual Muscle Testing System, model 01163, Lafayette, IN, USA).
The test was performed with the patient seated with his/her knees and hips flexed at 90°.
Resistance was applied to the anterior tibia during 5 seconds of maximal muscle contraction.
The test was repeated alternatively 3 times on the leg, allowing participants to rest between measurements.
The highest value in Newton was selected for the analysis.
|
Up to 9 days
|
|
Balance
Tidsramme: Baseline
|
Balance was evaluated by the one-leg standing balance test (OLS), that measured the time that the patient balances on one leg as long as possible.
The patient choose a leg to stand on (whichever he felt more comfortable with), flex the opposite knee allowing the foot to clear the floor, and balance on one leg.
Higher values mean better balance.
|
Baseline
|
|
Balance
Tidsramme: Up to 9 days
|
Balance was evaluated by the one-leg standing balance test (OLS), that measured the time that the patient balances on one leg as long as possible.
The patient choose a leg to stand on (whichever he felt more comfortable with), flex the opposite knee allowing the foot to clear the floor, and balance on one leg.
Higher values mean better balance.
|
Up to 9 days
|
|
Dyspnea
Tidsramme: Baseline
|
Dyspnea was assessed at rest using the modified Borg scale.
Patients classified their breathlessness from 0 (no dyspnea) to10 (maximal dyspnea)
|
Baseline
|
|
Dyspnea
Tidsramme: Up to 9 days
|
Dyspnea was assessed at rest using the modified Borg scale.
Patients classified their breathlessness from 0 (no dyspnea) to10 (maximal dyspnea)
|
Up to 9 days
|
|
Fatigue
Tidsramme: Baseline
|
Fatigue was evaluated using the Piper Fatigue Scale (PFS) that consists of 22 numerical items which assess multidimensional aspects of fatigue.
The scale measures four dimensions of subjective fatigue: "behavioral/severity", relating to the severity, distress, and degree of disruption in activity of daily living; "affective meaning", relating to the emotional meaning attributed to fatigue; "sensory", relating to the physical symptoms of fatigue; and "cognitive/mood", relating to mental and mood states
|
Baseline
|
|
Fatigue
Tidsramme: Up to 9 days
|
Fatigue was evaluated using the Piper Fatigue Scale (PFS) that consists of 22 numerical items which assess multidimensional aspects of fatigue.
The scale measures four dimensions of subjective fatigue: "behavioral/severity", relating to the severity, distress, and degree of disruption in activity of daily living; "affective meaning", relating to the emotional meaning attributed to fatigue; "sensory", relating to the physical symptoms of fatigue; and "cognitive/mood", relating to mental and mood states
|
Up to 9 days
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. desember 2019
Primær fullføring (Faktiske)
1. januar 2020
Studiet fullført (Forventet)
1. april 2020
Datoer for studieregistrering
Først innsendt
17. februar 2020
Først innsendt som oppfylte QC-kriteriene
2. mars 2020
Først lagt ut (Faktiske)
4. mars 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
4. mars 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. mars 2020
Sist bekreftet
1. mars 2020
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DF0089UG
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .